Arlene Lee Chow | Latham & Watkins LLP (2024)

Arlene Chow, a first-chair Chambers-ranked litigator and trial lawyer, represents companies in the life sciences, pharmaceutical, and biotechindustries on patent, trade secret, and licensing disputes. She serves as Global Vice Chair of the firm’s Healthcare & Life Sciences Industry Group.

Ms. Chow routinely litigates IP matters directed to small molecule and biologic drugs for the treatment of a wide variety of indications, as well as medical devices and dosage forms.Leveraging her background in biochemistry, Ms. Chowis able to frame matters from the perspective of a judge or jury in order to achieve the best solutions for her clients. Ms. Chow thrives on interaction with scientific experts, both in-house and externally.

Ms. Chow is a United States Patent and Trademark Office (USPTO) registered patent attorney, and one of a select few who has been first-chair not only in district court trials and hearings, but also federal circuit arguments, and inter partes and post grant review hearings before the USPTO.

Ms. Chow won the 2023 LMG Life Sciences Post-Grant Proceedings Attorney of the Year. She was shortlisted in the 2021 LMG Life Sciences Awards as General Patent Litigator of the Year for New York. In 2023, Ms. Chow was named one of the Notable Women in Law by Crain’s New York Business, a Woman Worth Watching in STEM by Diversity Journal, and one of the Top 250 Women in IP by Managing IP.

Ms. Chow previously served as Co- Chair of the firm’s Women Enriching Business (WEB) committee in the New York office.

Speaking Engagements

• Life Sciences Patent Network Conference, November 2022
• ACI Paragraph IV Disputes Master Symposium, September 2022
• Keynote Speaker, Women's Health Innovation Summit, September 2022
• Pharmaceutical Litigation Strategy Summit, September 2021

Ms. Chow’s experience includes representing:

• BASF as lead counsel in district court against CSIRO and Nuseed, defeating claims in 13 patents with claim construction, invalidity, and co-ownership determinations at pre-trial and jury trial
• Merck Sharpe & Dohme as lead counsel, successfully invalidating Pfizer patent claims relating to polysaccharide-protein conjugate vaccine formulations
• Amgen as lead counsel for patent owner, obtaining favorable written decision in inter partes review proceedings and at the Federal Circuit relating to method of refolding biologic proteins
• Merck Sharp & Dohme as lead counsel in Hatch-Waxman district court actions relating to diabetes drug
• Biogen as lead counsel in Hatch-Waxman district court actions relating to multiple sclerosis drug
• Astellas as lead counsel in Hatch-Waxman district court actions relating to overactive bladder drug
• Merck Animal Health as lead counsel, successfully defending against district court and post grant review proceedings brought by Boehringer Ingelheim Animal Health relating to swine vaccine patents
• Santen and Asahi Glass as lead counsel in multiple Hatch-Waxman and inter partes review proceedings, obtaining a favorable final decision upholding validity of glaucoma drug patent
• Merck Sharpe & Dohme in inter partes review proceedings adverse to GSK relating to polysaccharide-protein conjugate vaccine formulations
• Takeda as lead counsel, obtaining a permanent injunction in Hatch-Waxman bench trial on infringement and validity for anti-ulcer, anti-GERD drug
• Depomed as lead counsel for patent owner, obtaining favorable written decisions in inter partes review proceedings and at the Federal Circuit involving controlled release gastric retentive technology
• BASF as lead counsel in inter partes review proceeding adverse to Nuseed relating to transgenic plants making omega-3 fatty acids
• Photoscribe, a laser manufacturer, obtaining noninfringement, invalidity, and inequitable conduct determinations at bench and jury trials
• Qisda and BenQ, LCD monitor manufacturers, obtaining noninfringement determinations at ITC bench trial
• Millennium, obtaining summary judgment of invalidity determination in relation to urine drug testing protocols

*Certain matters were handled prior to joining Latham

Read More